SG11201808650QA - Methods of treating ocular conditions - Google Patents
Methods of treating ocular conditionsInfo
- Publication number
- SG11201808650QA SG11201808650QA SG11201808650QA SG11201808650QA SG11201808650QA SG 11201808650Q A SG11201808650Q A SG 11201808650QA SG 11201808650Q A SG11201808650Q A SG 11201808650QA SG 11201808650Q A SG11201808650Q A SG 11201808650QA SG 11201808650Q A SG11201808650Q A SG 11201808650QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- day
- rat
- pct
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 241000237502 Ostreidae Species 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- IMIPDPVHGGHVNH-YWVHRCQQSA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] (z)-octadec-9-enoate Chemical compound C1C[C@]2(C)C(=O)CC[C@H]2[C@@H]2CCC3=CC(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC=C3[C@H]21 IMIPDPVHGGHVNH-YWVHRCQQSA-N 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 235000020636 oyster Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111011101011101110110101011111111101111011111 International Bureau 0.. .1 j ..... ..,,/ (10) International Publication Number (43) International Publication Date WO 2017/177024 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: James; 107 1 / 4 Lanewood Avenue, Alhambra, California A61K 31/506 (2006.01) A61P 27/02 (2006.01) 91801 (US). MANDELL, Kenneth J.; 147 Lowell Street, A61K 45/00 (2006.01) A61P 27/04 (2006.01) Arlington, Massachusetts 02474 (US). A61K 9/00 (2006.01) (74) Agents: TONG, Connie C. et al.; COOLEY LLP, 1299 (21) International Application Number: Pennsylvania Avenue, NW Suite 700, Washington, District PCT/US2017/026385 of Columbia 20004-2400 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 6 April 2017 (06.04.2017) kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (26) Publication Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (30) Priority Data: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 62/319,648 7 April 2016 (07.04.2016) US MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (71) Applicant: OYSTER POINT PHARMA, INC. [US/US]; NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, One Sansome Street, #3630, San Francisco, California RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 94104 (US). TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: ACKERMANN, Douglas Michael; 13295 W Saddlebow Drive, Reno, Nevada 89511 (US). LOUDIN, = [Continued on next page] = (54) Title: = FM. = = = — — = = = = - _ = = — 11 .4 7r ei © IN IN 11 IN 11 © ei = = METHODS OF TREATING OCULAR CONDITIONS I Rat lattansaarAdmin 415% Co/appall:0 Day 1 olik-ftulta,A. -0-4 00 ,-0-ftalkor.30.0 R t attlraSEtt /Merlin 2% coMOiltiell Day 1 aa. -a- ,. : , Ttatiatsaehasat Ada& Ci% Carl oav 1 t. .., .,„ ... ...,........„ 1. poa 1 Rat lattanaaal Malin CS% Compound 1 Day 7 ^e-ma SW -40-rymatnevi -.•onta.,6.e , at hitfarlaSat Adrain 2% corn Day 7' -it- >A* Ow $ -4* Caroiod WO Rat intiventasat Adiala tairaataimaad 1 Day 7 t \"......,....„ -.-.... MO ... 0 , 4.0. , (AV (57) : Described herein are methods and pharmaceutical formula- tions for treating ocular conditions. O WO 2017/177024 Al I IIIII 110111011101011M110EM0M0111E110110110IE110V0IS (84) Designated States (unless otherwise indicated, for every SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, kind of regional protection available): ARIPO (BW, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, GH, SZ, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, Published: RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, CZ, IT, RS, DE, — LT, SE, with international search report (Art. 21(3))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319648P | 2016-04-07 | 2016-04-07 | |
| PCT/US2017/026385 WO2017177024A1 (en) | 2016-04-07 | 2017-04-06 | Methods of treating ocular conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808650QA true SG11201808650QA (en) | 2018-10-30 |
Family
ID=58549326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808650QA SG11201808650QA (en) | 2016-04-07 | 2017-04-06 | Methods of treating ocular conditions |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10709707B2 (en) |
| EP (2) | EP3439661B1 (en) |
| JP (2) | JP7090551B2 (en) |
| KR (2) | KR102512777B1 (en) |
| CN (3) | CN109310692B (en) |
| AU (1) | AU2017248276B2 (en) |
| BR (1) | BR112018070497A2 (en) |
| CA (1) | CA3020170A1 (en) |
| DK (1) | DK3439661T3 (en) |
| EA (1) | EA201892265A1 (en) |
| ES (1) | ES2893126T3 (en) |
| IL (3) | IL299204A (en) |
| MX (2) | MX2018012230A (en) |
| MY (1) | MY199237A (en) |
| NZ (1) | NZ746468A (en) |
| PH (1) | PH12018502154A1 (en) |
| PT (1) | PT3439661T (en) |
| SG (1) | SG11201808650QA (en) |
| TW (2) | TWI790997B (en) |
| WO (1) | WO2017177024A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| US9504644B2 (en) | 2014-10-20 | 2016-11-29 | Oyster Point Pharma, Inc. | Methods of increasing tear production |
| BR112018070497A2 (en) | 2016-04-07 | 2019-01-29 | Oyster Point Pharma Inc | pharmaceutical methods and formulations for treating eye conditions |
| TW202019417A (en) | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions |
| TW202019424A (en) | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | Methods of treating ocular conditions |
| TW202206078A (en) | 2020-04-28 | 2022-02-16 | 美商奧伊斯特普安生物製藥公司 | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
| KR20240021783A (en) * | 2021-05-07 | 2024-02-19 | 오이스터 포인트 파마 인코포레이티드 | Vector and nicotine agonist combination therapy |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277855B1 (en) * | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| US20030008892A1 (en) | 2001-07-09 | 2003-01-09 | Pfizer Inc. | Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| ES2258652T3 (en) | 2001-11-29 | 2006-09-01 | Pfizer Products Inc. | SUCCINATE SALTS OF 5,8,14-TRIAZATETRACICLO (10.3.1.02,11.04,9) -HEXADECA-2 (11), 3,5,7,9-PENTAENE AND PHARMACEUTICAL COMPOSITIONS OF THE SAME. |
| AU2003269413A1 (en) * | 2002-11-01 | 2004-05-25 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| US7098331B2 (en) | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
| US20060270592A1 (en) | 2004-03-19 | 2006-11-30 | Ophthalmic Research Associates, Inc. | Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
| WO2006040680A1 (en) | 2004-10-15 | 2006-04-20 | Pfizer Products Inc. | Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline |
| EP1885332A2 (en) | 2005-03-22 | 2008-02-13 | NicoNovum AB | Use of an artificial sweetener to enhance absorption of nicotine |
| US20110086086A1 (en) | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
| TWI405763B (en) | 2006-11-02 | 2013-08-21 | Targacept Inc | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes |
| EP2114970B1 (en) | 2007-02-02 | 2011-08-03 | Pfizer Products Inc. | Tricyclic compounds and their use as glucocorticoid receptor modulators |
| WO2008157365A2 (en) * | 2007-06-15 | 2008-12-24 | Targacept, Inc. | Vinylazacycloalkanes for treating neuropathic pain |
| US20090093446A1 (en) | 2007-10-05 | 2009-04-09 | Winston Laboratories, Inc. | Method for alleviating keratoconjunctivitis sicca |
| CL2008003507A1 (en) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Pharmaceutical composition comprising nicotine and a nicotinic acetylcholine receptor (nachr) opipramol desensitization inhibitor; pharmaceutical kit; medical device; and use to treat a disease or disorder of the central or peripheral nervous system. |
| AU2009221860A1 (en) | 2008-03-05 | 2009-09-11 | Targacept, Inc. | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes |
| WO2010028011A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| WO2010028033A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclooctanes and uses thereof |
| KR20110091501A (en) * | 2008-10-14 | 2011-08-11 | 싸이코제닉스 아이엔씨. | Nicotinic acetylcholine receptor ligands and the uses thereof |
| TW201024283A (en) | 2008-12-01 | 2010-07-01 | Targacept Inc | Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine |
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| EP3279195B1 (en) * | 2008-12-01 | 2020-07-01 | Oyster Point Pharma, Inc. | Synthesis and novel salt forms of (r)-5-((e)-2-pyrrolidin-3-ylvinyl)pyrimidine |
| CN102802630A (en) * | 2009-06-17 | 2012-11-28 | 塔加西普特公司 | Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| US8821457B2 (en) | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
| CA2852268C (en) | 2011-10-20 | 2020-08-25 | Novartis Ag | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
| US20140357971A1 (en) | 2011-11-30 | 2014-12-04 | Diagnostear Ltd. | Dry eye diagnostic |
| US9504644B2 (en) | 2014-10-20 | 2016-11-29 | Oyster Point Pharma, Inc. | Methods of increasing tear production |
| BR112018070497A2 (en) | 2016-04-07 | 2019-01-29 | Oyster Point Pharma Inc | pharmaceutical methods and formulations for treating eye conditions |
-
2017
- 2017-04-06 BR BR112018070497A patent/BR112018070497A2/en active Search and Examination
- 2017-04-06 DK DK17718304.3T patent/DK3439661T3/en active
- 2017-04-06 EA EA201892265A patent/EA201892265A1/en unknown
- 2017-04-06 US US16/091,830 patent/US10709707B2/en active Active
- 2017-04-06 CN CN201780034734.3A patent/CN109310692B/en active Active
- 2017-04-06 AU AU2017248276A patent/AU2017248276B2/en active Active
- 2017-04-06 KR KR1020237000103A patent/KR102512777B1/en active IP Right Grant
- 2017-04-06 ES ES17718304T patent/ES2893126T3/en active Active
- 2017-04-06 WO PCT/US2017/026385 patent/WO2017177024A1/en active Application Filing
- 2017-04-06 IL IL299204A patent/IL299204A/en unknown
- 2017-04-06 JP JP2018553080A patent/JP7090551B2/en active Active
- 2017-04-06 CA CA3020170A patent/CA3020170A1/en active Pending
- 2017-04-06 EP EP17718304.3A patent/EP3439661B1/en active Active
- 2017-04-06 PT PT177183043T patent/PT3439661T/en unknown
- 2017-04-06 TW TW106111559A patent/TWI790997B/en active
- 2017-04-06 EP EP21189296.3A patent/EP3970724A1/en active Pending
- 2017-04-06 CN CN202210034408.5A patent/CN114533737B/en active Active
- 2017-04-06 SG SG11201808650QA patent/SG11201808650QA/en unknown
- 2017-04-06 MX MX2018012230A patent/MX2018012230A/en unknown
- 2017-04-06 CN CN202210040168.XA patent/CN114432313A/en active Pending
- 2017-04-06 TW TW112102845A patent/TW202320785A/en unknown
- 2017-04-06 KR KR1020187032218A patent/KR102485299B1/en active IP Right Grant
- 2017-04-06 NZ NZ746468A patent/NZ746468A/en unknown
- 2017-04-06 MY MYPI2018001700A patent/MY199237A/en unknown
-
2018
- 2018-10-03 IL IL262102A patent/IL262102B/en unknown
- 2018-10-05 PH PH12018502154A patent/PH12018502154A1/en unknown
- 2018-10-05 MX MX2021010399A patent/MX2021010399A/en unknown
-
2020
- 2020-04-17 US US16/852,225 patent/US20200345734A1/en active Pending
-
2022
- 2022-01-24 IL IL290069A patent/IL290069B2/en unknown
- 2022-06-14 JP JP2022095460A patent/JP2022120125A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808650QA (en) | Methods of treating ocular conditions | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201901445TA (en) | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201903938XA (en) | Acylated glp-1/glp-2 dual agonists | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |